A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 May 2018 Biomarkers information updated
- 30 Aug 2013 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov.
- 30 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.